..
Novartis Vaccines and Diagnostics, Inc.
4560 Horton Street
Emeryville
California
94608
U.S.A.
Phone:
510-655-8730
Fax:
510-923-3376
|
Novartis provides healthcare solutions that address the evolving needs of patients and societies. In Emeryville, CA, Novartis has two divisions, Novartis Diagnostics and Novartis Institutes for BioMedical Research (NIBR).
Novartis Diagnostics, headquartered in Emeryville, California, is the established global leader in blood safety, a position built on more than 20 years of scientific excellence, ongoing innovation, and collaboration with our development partners. Worldwide, more of the 89 million units of donated blood are tested with Novartis than any other NAT system. But there’s still more work to be done to address unmet medical needs. Building on its strong presence in transfusion medicine, Novartis Diagnostics is creating innovative diagnostics to detect, prevent and predict disease and to improve medical outcomes.
Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis committed to discovering innovative medicines that treat disease and improve human health. At NIBR Emeryville, our Oncology team of over 200 scientists covers a broad spectrum of expertise including signal transduction pathways, cell cycle control, pharmacology, biologics research, structural biology and medicinal and computational chemistry. An exciting array of therapeutics in the clinic are targeting key signaling nodes. Oncology concentrates on common solid tumors such as prostate cancer, breast cancer and melanoma, on rare tumors such as medulloblastoma and multiple myeloma, and on chronic myelogenic leukemia.
For more information on Novartis, visit the Novartis Diagnostics and the Novartis Institutes for BioMedical Research websites.
Email:
Ownership:
Subsidiary
Web Site:
Novartis Vaccines and Diagnostics, Inc.
Employees:
Symbol: NVS
|
|
|
Company News |
Trimeris, Inc. (TRMS) and Roche (RHHBY) Paying More Than $2.4 Million to Settle Fuzeon Patent Dispute With Novartis Vaccines & Diagnostics, Inc. (NVS)
9/27/2010 8:05:30 AM
More...
|
Novartis Vaccines & Diagnostics, Inc. (NVS) Begins Shipment of Seasonal Influenza Vaccine Fluvirin(R) to U.S. Market to Help Protect Ahead of 2010-2011 Flu Season
7/30/2010 9:48:44 AM
More...
|
Talecris Biotherapeutics (TLCR) Forms Partnership to Co-Promote Life-Saving Rabies Products
6/16/2010 10:17:08 AM
More...
|
Talecris Biotherapeutics GmbH Forms Partnership to Co-Promote Life-Saving Rabies Products
6/15/2010 2:54:41 PM
More...
|
FDA Accepts Novartis Vaccines & Diagnostics, Inc. (NVS)'s sBLA to Expand Indication of Menveo(R) to Children 2-10 Years of Age
5/10/2010 11:35:24 AM
More...
|
Novartis Vaccines & Diagnostics, Inc. (NVS), Novartis Pharmaceuticals Corporation (NVS) to Pay $72.5 Million to Settle US False Claims
5/5/2010 7:11:25 AM
More...
|
BioMimetic Therapeutics, Inc. (BMTI) Strengthens its Agreement with Novartis Vaccines & Diagnostics, Inc. (NVS) for Exclusive Supply of rhPDGF-BB
1/7/2010 10:01:32 AM
More...
|
US Government and Novartis AG in $486 Million Flu Vaccine Deal
1/15/2009 8:13:18 AM
More...
|
XOMA Ltd. Restructures Drug Development Collaboration with Novartis Vaccines & Diagnostics, Inc. (NVS) Including Oncology Drug Candidate HCD122
11/10/2008 7:37:33 AM
More...
|
FDA Approves 2008-2009 Season's Flu Vaccines: CSL Limited (CMXHF.PK), Afluria. GlaxoSmithKline Biologicals (GSK), Fluarix. ID Biomedical Corporation (IDBE) of Quebec, FluLaval. MedImmune Vaccines, FluMist. Novartis Vaccines & Diagnostics, Inc. (NVS), Fluvirin. Sanofi Pasteur (SASY.PA), Fluzone.
8/6/2008 6:31:10 AM
More...
|
|
|
|